466 related articles for article (PubMed ID: 35098327)
1. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.
Li M; Younis MH; Zhang Y; Cai W; Lan X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2844-2868. PubMed ID: 35098327
[TBL] [Abstract][Full Text] [Related]
2.
Giesel FL; Kratochwil C; Lindner T; Marschalek MM; Loktev A; Lehnert W; Debus J; Jäger D; Flechsig P; Altmann A; Mier W; Haberkorn U
J Nucl Med; 2019 Mar; 60(3):386-392. PubMed ID: 30072500
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging.
Schmidkonz C; Kuwert T; Atzinger A; Cordes M; Schett G; Ramming A; Götz T
J Nucl Med; 2022 Dec; 63(12):1786-1792. PubMed ID: 36109182
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Activation Protein Inhibitor PET/CT: A Promising Molecular Imaging Tool.
Sharma P; Singh SS; Gayana S
Clin Nucl Med; 2021 Mar; 46(3):e141-e150. PubMed ID: 33351507
[TBL] [Abstract][Full Text] [Related]
5. Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma:
Watabe T; Liu Y; Kaneda-Nakashima K; Shirakami Y; Lindner T; Ooe K; Toyoshima A; Nagata K; Shimosegawa E; Haberkorn U; Kratochwil C; Shinohara A; Giesel F; Hatazawa J
J Nucl Med; 2020 Apr; 61(4):563-569. PubMed ID: 31586001
[TBL] [Abstract][Full Text] [Related]
6. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.
Lindner T; Loktev A; Altmann A; Giesel F; Kratochwil C; Debus J; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2018 Sep; 59(9):1415-1422. PubMed ID: 29626119
[TBL] [Abstract][Full Text] [Related]
7. Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
Loktev A; Lindner T; Burger EM; Altmann A; Giesel F; Kratochwil C; Debus J; Marmé F; Jäger D; Mier W; Haberkorn U
J Nucl Med; 2019 Oct; 60(10):1421-1429. PubMed ID: 30850501
[TBL] [Abstract][Full Text] [Related]
8. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT.
Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723
[TBL] [Abstract][Full Text] [Related]
9. Design and Development of
Lindner T; Altmann A; Krämer S; Kleist C; Loktev A; Kratochwil C; Giesel F; Mier W; Marme F; Debus J; Haberkorn U
J Nucl Med; 2020 Oct; 61(10):1507-1513. PubMed ID: 32169911
[TBL] [Abstract][Full Text] [Related]
10. Relationship Between Cardiac Fibroblast Activation Protein Activity by Positron Emission Tomography and Cardiovascular Disease.
Heckmann MB; Reinhardt F; Finke D; Katus HA; Haberkorn U; Leuschner F; Lehmann LH
Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010628. PubMed ID: 32912030
[TBL] [Abstract][Full Text] [Related]
11. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
[TBL] [Abstract][Full Text] [Related]
12. Advancement and Future Perspective of FAPI PET/CT In Gynecological Malignancies.
Dendl K; Koerber SA; Tamburini K; Mori Y; Cardinale J; Haberkorn U; Giesel FL
Semin Nucl Med; 2022 Sep; 52(5):628-634. PubMed ID: 35842334
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and Therapeutic Application of Fibroblast Activation Protein Inhibitors in Oncologic and Nononcologic Diseases.
Nakayama M; Hope TA; Salavati A
Cancer J; 2024 May-Jun 01; 30(3):210-217. PubMed ID: 38753756
[TBL] [Abstract][Full Text] [Related]
14. In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA
Moon ES; Van Rymenant Y; Battan S; De Loose J; Bracke A; Van der Veken P; De Meester I; Rösch F
Molecules; 2021 Jun; 26(12):. PubMed ID: 34201111
[TBL] [Abstract][Full Text] [Related]
15. Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an
Toms J; Kogler J; Maschauer S; Daniel C; Schmidkonz C; Kuwert T; Prante O
J Nucl Med; 2020 Dec; 61(12):1806-1813. PubMed ID: 32332144
[TBL] [Abstract][Full Text] [Related]
16. Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review.
Zhao L; Chen J; Pang Y; Fu K; Shang Q; Wu H; Sun L; Lin Q; Chen H
Theranostics; 2022; 12(4):1557-1569. PubMed ID: 35198057
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine.
Giammarile F; Knoll P; Paez D; Estrada Lobato E; Calapaquí Terán AK; Delgado Bolton RC
Semin Nucl Med; 2024 May; 54(3):340-344. PubMed ID: 38365545
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast Activation Protein Inhibitor Tracers and Their Preclinical, Translational, and Clinical Status in China.
Zhao L; Kang F; Pang Y; Fang J; Sun L; Wu H; Lan X; Wang J; Chen H
J Nucl Med; 2024 May; 65(Suppl 1):4S-11S. PubMed ID: 38719234
[TBL] [Abstract][Full Text] [Related]
19. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.
Sollini M; Kirienko M; Gelardi F; Fiz F; Gozzi N; Chiti A
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4396-4414. PubMed ID: 34173007
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Considerations.
Kaneda-Nakashima K; Shirakami Y; Kadonaga Y; Watabe T
PET Clin; 2023 Jul; 18(3):397-408. PubMed ID: 36997365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
